The USPTO issued Patent US12595305B2 to Novartis AG on April 7, 2026, covering antibodies that bind to and stabilize human TREM2 protein and methods of using these antibodies. The application was filed on September 23, 2022, and the patent grants Novartis exclusive proprietary rights to this TREM2 stabilizing antibody technology.

For pharmaceutical and biotech companies developing TREM2-targeting therapies, this patent establishes Novartis's intellectual property position in this therapeutic space. Competitors working on similar neurodegeneration or immunology therapies may need to conduct freedom-to-operate analyses or explore licensing arrangements with Novartis.